Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

Abstract Introduction To assess changes in the Patient-Reported Outcomes Measurement Information System (PROMIS®) outcomes related to social, mental, and physical well-being after approximately 1 year of intravenous (IV) golimumab or infliximab treatment in patients with rheumatoid arthritis (RA) us...

Full description

Bibliographic Details
Main Authors: Clifton O. Bingham, Shawn Black, Natalie J. Shiff, Stephen Xu, Wayne Langholff, Jeffrey R. Curtis
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-02-01
Series:Rheumatology and Therapy
Subjects:
Rheumatoid arthritis
PROMIS
Patient-reported outcomes
Intravenous golimumab
Infliximab
Depression
Online Access:https://doi.org/10.1007/s40744-023-00533-5

Internet

https://doi.org/10.1007/s40744-023-00533-5

Similar Items